SPECIALTY QUANTITY LIMIT PROGRAM

KISQALI (ribociclib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

| Medication | Standard Limit | FDA-recommended dosing |
|-------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kisqali (ribociclib) 200 mg tablet | 63 tablets per 28 days | Breast Cancer: The recommended dose is 600 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Dose modifications for adverse reactions: First dose reduction: Kisqali 400 mg per day for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Second dose reduction: Kisqali 200 mg/day for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. |
| Kisqali (ribociclib) 600 mg daily dose carton [contains three blister packs with 21 200-mg tablets each] | 63 tablets per 28 days | |
| Kisqali (ribociclib) 400 mg daily dose carton [contains two blister packs with 21 200-mg tablets each] | 42 tablets per 28 days | |
| Kisqali (ribociclib) 200 mg daily dose carton [contains one blister packs with 21 200-mg tablets each] | 21 tablets per 28 days | |

III. REFERENCE

1. Kisqali [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2020.

Specialty Quantity Limit Kisqali 1652-H P2019b.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

